Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Adverum Biotechnlgs (ADVM)

Adverum Biotechnlgs (ADVM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 998,534
  • Shares Outstanding, K 80,657
  • Annual Sales, $ 250 K
  • Annual Income, $ -64,490 K
  • 60-Month Beta 1.70
  • Price/Sales 4,139.32
  • Price/Cash Flow N/A
  • Price/Book 3.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.39
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.00 +4.36%
on 09/04/20
13.31 -13.75%
on 09/16/20
-1.49 (-11.49%)
since 08/21/20
3-Month
11.00 +4.36%
on 09/04/20
26.98 -57.45%
on 06/23/20
-13.15 (-53.39%)
since 06/19/20
52-Week
4.96 +131.45%
on 10/10/19
26.98 -57.45%
on 06/23/20
+5.04 (+78.26%)
since 09/20/19

Most Recent Stories

More News
Adverum Biotechnologies Announces Appointment of Christopher J. Morrison, Ph.D. as Vice President, Process Science

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Christopher J. Morrison, Ph.D. joined...

ADVM : 11.60 (-6.30%)
Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the company will present at the Cantor...

ADVM : 11.60 (-6.30%)
New Strong Sell Stocks for September 8th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

JBLU : 11.51 (-9.01%)
ADVM : 11.60 (-6.30%)
KDMN : 4.30 (-4.44%)
ALPN : 8.01 (-7.61%)
PRVB : 13.91 (-8.49%)
Adverum Biotechnologies Announces Closing of $217 Million Public Offering of Common Stock

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the closing of its previously announced underwritten...

ADVM : 11.60 (-6.30%)
Adverum (ADVM) Surges: Stock Moves 6.2% Higher

Adverum (ADVM) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

ADVM : 11.60 (-6.30%)
AVXL : 4.11 (-3.29%)
Adverum Biotechnologies Announces Pricing of Public Offering of Common Stock

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the pricing of its underwritten public offering...

ADVM : 11.60 (-6.30%)
Adverum Biotechnologies Announces $200 Million Public Offering of Common Stock

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has commenced an underwritten public...

ADVM : 11.60 (-6.30%)
Adverum Biotechnologies (ADVM) Reports Q2 Loss, Lags Revenue Estimates

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -20.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?...

ADVM : 11.60 (-6.30%)
Adverum Biotechnologies: 2Q Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Adverum Biotechnologies Inc. (ADVM) on Monday reported a loss of $29.2 million in its second quarter.

ADVM : 11.60 (-6.30%)
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter 2020 Financial Results

-- Continued robust treatment response from both high and low doses --

ADVM : 11.60 (-6.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade ADVM with:

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

2nd Resistance Point 13.52
1st Resistance Point 12.95
Last Price 11.60
1st Support Level 11.94
2nd Support Level 11.50

See More

52-Week High 26.98
Fibonacci 61.8% 18.57
Fibonacci 50% 15.97
Fibonacci 38.2% 13.37
Last Price 11.60
52-Week Low 4.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar